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he L1 adhesion molecule plays an important role in
axon guidance and cell migration in the nervous
system. L1 is also expressed by many human carcino-
mas. In addition to cell surface expression, the L1
ectodomain can be released by a metalloproteinase, but
the biological function of this process is unknown. Here
we demonstrate that membrane-proximal cleavage of L1 can
be detected in tumors and in the developing mouse brain. The
shedding of L1 involved a disintegrin and metalloproteinase
(ADAM)10, as transfection with dominant-negative ADAM10
completely abolishes L1 release. L1-transfected CHO
cells (L1-CHO) showed enhanced haptotactic migration
on ﬁbronectin and laminin, which was blocked by anti-
T
 
bodies to 
 
 
 
v
 
 
 
5
 
 and L1. Migration of L1-CHO cells, but
not the basal migration of CHO cells, was blocked by a
metalloproteinase inhibitor, indicating a role for L1 shedding
in the migration process. CHO and metalloproteinase-
inhibited L1-CHO cells were stimulated to migrate by soluble
L1-Fc protein. The induction of migration was blocked by
 
 
 
v
 
 
 
5
 
-speciﬁc antibodies and required Arg-Gly-Asp sites in
L1. A 150-kD L1 fragment released by plasmin could also
stimulate CHO cell migration. We propose that
ectodomain-released L1 promotes migration by autocrine/
paracrine stimulation via 
 
 
 
v
 
 
 
5.
 
 This regulatory loop could
be relevant for migratory processes under physiological
and pathophysiological conditions.
 
Introduction
 
The regulation of cell migration is of paramount importance
for many cellular processes. During embryogenesis, cells
migrate long distances before reaching their destination. A
well-studied example is the formation of the nervous system.
The cerebral cortex extends axons long distances to various
cortical and subcortical structures. Cell surface receptors that
transduce signals from environmental cues direct the guid-
ance of these axons. Environmental cues include diffusible
and nondiffusible molecules that can be attractant and/or
repellent. Examples include growth factors, semaphorins,
netrins, cell adhesion molecules, and extracellular matrix
molecules (Tessier-Lavigne and Goodman, 1996). Cell mi-
gration remains important in the adult organism in a variety
of organ systems. During tumor metastasis, for example,
released tumor cells migrate from the primary tumor into
the circulatory system, and then invade a new site (Fidler,
1990). Cell adhesion and migration are mediated in many
instances by cell surface integrins that link interactions with
the substratum to the cytoskeleton inside the cell. Integrins
are heterodimeric cell adhesion molecules that were initially
found to mediate the interaction of cells to components of the
extracellular matrix like laminin, fibronectin, vitronectin, etc.
(Hynes, 1992). Integrin binding and clustering initiates not
only adhesion, but also activates many intracellular signaling
events that regulate diverse cell functions such as cell migra-
tion, polarity, survival, or cell growth (for review see Gian-
cotti and Ruoslahti, 1999; Schwartz and Shattil, 2000)
L1 is a 200–220-kD type I membrane glycoprotein of the
immunoglobulin family, consisting of 6 Ig-like domains and
five fibronectin-type III repeats, followed by a transmem-
brane region and a highly conserved cytoplasmic tail. In
neuronal cells, L1 is involved in several morphogenic events,
such as neuron–neuron adhesion, neurite fasciculation, syn-
aptogenesis, neurite outgrowth on Schwann cells and neu-
ronal cell migration (for review see Hortsch, 1996;
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Schachner, 1997, Brümmendorf et al., 1998). Although ini-
tially characterized and most extensively studied in the ner-
vous system, L1 is expressed also by hematopoietic and cer-
tain epithelial cells (Kowitz et al., 1992; Ebeling et al., 1996,
Pancook et al., 1997; Debiec et al., 1998) and a variety of
human tumor cell lines such as neuroblastomas, melanomas,
and lung carcinomas (Linnemann et al., 1989; Patel et al.,
1991; Reid and Hemperly, 1992; Katayama et al., 1997),
suggesting a potential role of the molecule in other adhesion
and migration events. L1 supports cellular processes through
interaction with extracellular ligands and transduction of a
variety of signaling events through associated proteins (Ka-
miguchi and Lemmon, 1997; Brümmendorf et al., 1998;
Doherty et al., 2000). L1 can undergo homophilic L1-L1
binding involving several Ig domains (De Angelis et al.,
1999), and can interact via Ig domain 1 with the proteogly-
can neurocan (Oleszewski et al., 1999). The Arg-Gly-Asp
(RGD)* sites in Ig domain 6 of L1 support heterophilic
binding to integrins including 
 
 
 
5
 
 
 
1, 
 
 
 
v
 
 
 
1, and 
 
 
 
v
 
 
 
3, as
well as the platelet integrin 
 
 
 
IIb
 
 
 
3 (Ruppert et al., 1995;
Ebeling et al., 1996; Montgomery et al., 1996; Felding-
Habermann et al., 1997; Oleszewski et al., 1999). Recently,
an RGD-independent binding site for 
 
 
 
9
 
 
 
1 was identified
in the third fibronectin (FN)III domain (Silletti et al.,
2000). In addition to the cell surface localization, L1 can be
released as a soluble molecule from mouse cerebellar cells in
culture (Sadoul et al., 1988) and from mouse and human tu-
mor cells (Montgomery et al., 1996; Beer et al., 1999; Gut-
wein et al., 2000). We have shown before that L1 release
involves membrane-proximal cleavage by an unknown me-
talloproteinase, most likely of the a disintegrin and metallo-
proteinase (ADAM) family (Gutwein et al., 2000). An in-
creasing number of soluble proteins are now recognized as
being derived from integral plasma membrane proteins (for
review see Schlöndorff and Blobel, 1999; Turner and
Hooper, 1999; Blobel, 2000). These proteins are diverse in
structure and function, and comprise molecules such as
TNF-
 
 
 
, FasL, IL-6 receptor, L-selectin, pro–TGF-
 
 
 
, and
amyloid precursor protein (APP) (for review see Turner and
Hooper, 1999). Members of the ADAM family (membrane
proteins composed of a disintegrin and metalloproteinase
domain) were shown to be important in ectodomain release
(for review see Black and White, 1998; Schlöndorff and Blo-
bel, 1999). ADAM17/TACE mediates the membrane re-
lease of TNF-
 
 
 
, L-selectin, and TGF-
 
 
 
 (Peschon et al.,
1998). ADAM10/Kuz has been described as 
 
 
 
-secretase for
the cleavage of APP (Lammich et al., 1999), and ADAM9 is
involved in the phorbolester-induced ectodomain shedding
of membrane-anchored heparin-binding EGF-like growth
factor (HB-EGF) (Izumi et al., 1998, Gechtman et al.,
1999). Recent reports have established an important link be-
tween ectodomain cleavage by metalloproteinases and the
regulation of migratory processes. The function of the ax-
onal chemoattractant Netrin-1 is regulated by cleavage of its
receptor, deleted in colorectal cancer (DCC). Blocking of
cleavage by a metalloproteinase inhibitor potentiated axon
 
outgrowth (Galko and Tessier-Lavigne, 2000). The contact-
mediated axon repulsion by ephrin-A2 involves cleavage by
Kuz, which is triggered by binding of the A2 ligand Eph re-
ceptor (Hattori et al., 2000). This proteolytic process allows
efficient axon detachment and withdrawal. Finally, a recent
study has shown that ectodomain shedding of EGF receptor
ligands is required for keratinocyte migration in cutaneous
wound healing (Tokumaru et al., 2000). It was hypothesized
that the inhibition of EGF receptor ligand shedding abro-
gated the auto/paracrine stimulation of soluble EGF recep-
tor ligands, which is critical for keratinocyte migration.
In the light of these published results, we have examined
the possible biological role of L1 ectodomain shedding.
Given the known involvement of L1 in cell migratory pro-
cesses, we have specifically addressed the question whether
the ectodomain release of L1 might have a decisive part in
such events. In the present report, we provide evidence that
membrane-proximal cleavage of L1 can be detected in tu-
mor cell lines and in the developing mouse brain. In andro-
gen receptor (AR) breast tumor cells, the shedding of L1 in-
volves ADAM10, as transfection with dominant-negative
ADAM10 completely abolishes L1 release. We also demon-
strate that cleavage of L1 stimulates cell migration on fi-
bronectin and laminin by autocrine binding of soluble L1 to
 
 
 
v
 
 
 
5 integrins. These observations have important implica-
tions for understanding how L1 can function to promote
cell migration in the nervous system, as well as how L1 ex-
pression in tumors could contribute to dissemination and
metastasis.
 
Results
 
A 32-kD cytoplasmic fragment of L1 is retained in the 
membrane after release of the L1 ectodomain
 
Soluble L1 is present in the culture medium of various L1-pos-
itive mouse and human carcinoma cell lines (Beer et al., 1999;
Gutwein et al., 2000). The release from the cell surface re-
quires proteolytic cleavage of the ectodomain, which in ad-
herent cells is induced by detachment with EDTA and in-
cubation at 37
 
 
 
C (Gutwein et al., 2000). To identify the
COOH-terminal cleavage product and to further investigate
the cleavage process, a polyclonal antibody against the cyto-
plasmic tail of L1 (pcytL1) was used. L1-transfected CHO cells
(CHO-L1) were incubated in suspension at 37
 
 
 
C for 1 h, and the
cell pellets were lysed and analyzed by Western blotting. As shown
in Fig. 1 A, pcytL1 detected protein bands at 220, 85, and 32
kD in CHO-L1 cells, but not in untransfected CHO cells. A
mAb against the ectodomain of human L1 (UJ 127.11) re-
acted with the 220- and the 85-kD fragment, but not with the
32-kD fragment (Fig. 1 A). The latter band was also not de-
tected by pcytL1 in CHO cells transfected with mouse L1 car-
rying a deletion of the cytoplasmic portion (unpublished
data). This suggested that a 32-kD fragment comprising the
COOH-terminal portion of L1 remained associated with the
membrane after cleavage. The protein bands at 220 kD repre-
sents full-length L1. The 85-kD L1 fragment represents the
COOH-terminal fragment after proteolytic cleavage of L1 in
the third FNIII repeat which contains the dibasic sequence
QRKHSKRHIH (Fig. 1 B). Serine proteases like plasmin
 
*
 
Abbreviations used in this paper: ADAM,
 
 
 
a disintegrin and metallopro-
teinase; APP, amyloid precursor protein; AR, androgen receptor; FN, fi-
bronectin;
 
 
 
MCD, methyl-
 
 
 
-cyclodextrin; RGD, Arg-Gly-Asp. 
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(Nayeem et al., 1999) can cleave at this site and release a solu-
ble 140–150-kD fragment into the supernatant (see below).
L1-positive tumor cell lines were tested for the presence of
the 32-kD cleavage fragment. As shown in Fig. 2 A, the 32-kD
fragment was clearly detected in lysates from the breast carci-
noma lines AR and SKBR3, but only minor amounts were de-
tected in MDA-231, MDA-435, or SKOV3 cell lysates. As
shown by Western blot analysis in Fig. 2 B and by capture
ELISA in Fig. 2 C, the level of shed L1 in the supernatants
paralleled the presence of L1-32 in the cell lysate. A close cor-
relation between the amount of L1 in the supernatant and the
level of L1 expression was noted, suggesting that the release of
L1 is an intrinsic property of many human tumor lines.
Treatment of attached cells with PMA or pervanadate also
induced shedding of L1 that can be blocked by hydroxa-
mate-based metalloproteinase inhibitors (Gutwein et al.,
2000). We examined the presence of L1-32 in AR cells after
induction of cleavage in the absence or presence of BB-3103
metalloproteinase inhibitor. As shown in Fig. 3 A, dramati-
cally increased levels of soluble L1 were detected in the su-
pernatant after PMA (lane 2) or pervanadate treatment (lane
4) that were reduced to background levels in the presence of
BB-3103 (lanes 3 and 5). Surprisingly, enhanced L1 release
was observed by treatment of cells with methyl-
 
 
 
-cyclodex-
trin (MCD) (lane 6), a drug known to interfere with mem-
brane cholesterol levels. Also, the MCD-induced release of
L1 was inhibited by BB-3103 (lane 7). As shown in Fig. 3 B,
the induction of L1 cleavage by PMA, pervanadate, or
MCD clearly augmented the presence of L1-32 from a basal
level in untreated cells. Collectively, the data suggested that
L1-32 represents the portion of L1 remaining associated
with the cells after shedding of the ectodomain.
 
Ectodomain cleavage of L1 occurs in the developing 
mouse brain
 
L1 plays an important role in brain development. We exam-
ined the possibility that ectodomain cleavage of L1 occurred
in vivo. Mouse brains of different ages were lysed, and equal
amounts of protein were analyzed by Western blotting using
pcytL1. To avoid post-lysis cleavage of L1, the lysates were
prepared in the presence of 10 mM EDTA and 2 mM 1,10
phenanthroline, conditions that are known to block metallo-
proteinase activity. As shown in Fig. 4, L1-32 was most
prominent in newborn P1 mice but declined at later stages.
The low level of L1-220 and the absence of L1-85 in E15
brain is in agreement with earlier studies using rat brain (Lil-
jelund et al., 1994). Densitometric analysis of band intensi-
ties revealed a L1-220/L1-32 ratio of approximately 4:1 in
P1 brain that changed at later ages. This suggests that the
level of L1-32 cleavage is highest in P1 brain, but the onset
of cleavage probably occurred earlier. These data confirm
and extend the results of Liljelund, showing that the expres-
sion of L1 and the proteolytic cleavage are developmentally
regulated.
 
Expression of L1 augments cell migration
 
Having established that ectodomain cleavage of L1 occurs in
human tumor cells and during mouse brain development,
Figure 1.  L1 is shed without cytoplasmic tail. (A) 
CHO or L1-transfected CHO cells were incubated 
at 37 C in suspension in medium without FCS for
1 h. The cell pellet was lysed and analyzed by 
Western blot with mAb UJ127.11 to the ecto-
domain or pcytL1 to the cytoplasmic domain
of L1. (B) Schematic representation of L1 cleavage 
fragments and their relative localization. The 
location of antibody recognition sites are 
indicated. (1), mAb 5G3; (2), mAb UJ 127.11; 
(3) pcytL1.
Figure 2.  Presence of a L1-32 indicates 
membrane-proximal cleavage. Cells were 
incubated at 37 C in suspension in medium 
without FCS for 1 h (A) Cell pellets were lysed 
and blotted with pcytL1 followed by ECL 
detection. Note that a parallel blot using the 
secondary antibody only was negative. (B) Super-
natants were analyzed for the presence of shed 
L1 using blotting with mAb UJ127.11 to the 
ectodomain of human L1 followed by ECL 
detection. (C) Supernatants were also probed for 
the presence of soluble L1 using a capture ELISA. 
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we set out to explore the physiological role of the shedding
process. In the brain, L1 plays an important role in the mi-
gration of neural cells. Therefore, we examined the role of
L1 and its ectodomain cleavage process in cell migration. As
shown in Fig. 5 A, we observed that CHO cells stably trans-
fected with mouse or human L1 (mL1-CHO or hL1-CHO
cells) showed a three- to fivefold increase in haptotactic mi-
gration on fibronectin compared with CHO cells. In con-
trast, CHO cells expressing L1 in which both RGD sites
were mutated to RGE (mL1-mutIII-CHO) or those express-
ing mutant forms of L1 containing either the cytoplasmic
and transmembrane portion of L-selectin (L1/L-selectin) or
the ectodomain of L-selectin (L-selectin/L1) did not show
increased migration (Fig. 5 A). The transfected CHO cells
expressed L1 or the chimeric forms of L1 at comparable level
as detected by FACS analysis (Fig. 5 B).
A similar difference in cell migration between mL1-CHO
or CHO cells was also observed on vitronectin or laminin as
the migration substrate (Fig. 5 C and see below). As shown
in the dose–response curve in Fig. 5 D, the difference in mi-
gration between CHO and mL1-CHO cells was detectable
over a wide range of input cell numbers (between 10
 
4
 
 and
5 
 
  
 
10
 
5
 
). To exclude the possibility that the transfection
had altered the integrin profiles, the static adhesion to fi-
bronectin was examined. As shown in Fig. 5 E, there was no
difference in the adhesion to fibronectin between CHO cells
and transfected sublines. Similar observations were made
with vitronectin as substrate (unpublished data). The adhe-
sion of CHO and mL1-CHO cells to fibronectin was
blocked in both cases with mAb SAM-1 to the 
 
 
 
5 integrin
that is highly expressed by CHO cells (unpublished data).
To analyze whether the structural changes introduced into
L1 had affected the membrane localization, cells were also
analyzed by fluorescent microscopy (Fig. 5 F). The mem-
brane localization of mL1-mutIII was not different from
wild-type L1. In contrast, CHO-62 cells carrying the cyto-
plasmic tail of L-selectin showed a different L1 distribution.
In addition to surface staining (Fig. 5 B), L1 was localized in
a region close to the nucleus. The cells appeared also larger
in morphology with a more rounded-up appearance. De-
spite their inability to migrate, CHO-62 cells released signif-
icantly more L1 into the supernatant than wild-type CHO-
L1 cells (Fig. 5 G).
 
The 
 
 
 
v
 
 
 
5 integrin is involved in enhanced
cell migration
 
We investigated the difference in migration between mL1-
CHO cells and CHO cells in more detail using blocking
mAbs. As shown in Fig. 6 A, mAb P1F6 to human 
 
 
 
v
 
 
 
5
crossreacted with hamster integrins and could inhibit the
migration of mL1-CHO cells to the level of CHO cells. Im-
portantly, there was no effect of the 
 
 
 
v
 
 
 
5-specific mAb on
the migration of CHO cells. Additional FACS analysis with
mAb P1F6 showed no difference in the expression level of
the 
 
 
 
v
 
 
 
5 integrin (Fig. 6 B). The migration of mL1-CHO
was also efficiently blocked in the presence of mAb 324
against mouse L1, but not by the isotype-matched control
mAb 79 (Fig. 6 A).
To rule out the possibility that CHO and mL1-CHO
cells used different integrins to migrate on fibronectin, addi-
tional blocking experiments were carried out. As shown in
Fig. 6 D, mAb SAM-1 to the 
 
 
 
5 integrin also could effi-
ciently block the transmigration. Most importantly, both
CHO and mL1-CHO cells were equally well blocked by the
mAb. These results indicated that altered integrin levels or
altered integrin usage were not the reason for the improved
cell migration of L1-CHO cells.
We also reinvestigated the migration of CHO and mL1-
CHO cells on laminin. The migration of both type of cells
was nearly completely blocked by mAb GoH3 against
CD49f. Similar to fibronectin, mAb P1F6 to the 
 
 
 
v
 
 
 
5 inte-
grin did not affect the migration of CHO cells, but the en-
hanced migration of mL1-CHO cells was reduced again to
the level of CHO cells (unpublished data). We concluded
that in transfected cells the presence of L1 led to an en-
hanced cell migration on different substrates that specifically
involved the 
 
 
 
v
 
 
 
5 integrin, and that the elimination of
RGDs in L1 abolished the augmenting effect on cell migra-
tion (Figs. 5 A and 6 A).
Figure 3.  Regulated cleavage of L1 is blocked by metalloprotein-
ase inhibitor. Attached AR cells were treated with PMA (100 ng/ml), 
pervanadate (200 mmolar), or MCD for 1 h at 37 C in the absence 
or presence of BB-3103 inhibitor. (A) Supernatants were immuno-
precipitated with mAb to L1 coupled to Sepharose and analyzed for 
shed L1 using blotting with mAb UJ127.11 followed by ECL detec-
tion. (B) Cell pellets were lysed and blotted with pcytL1 followed by 
ECL detection.
Figure 4.  L1-32 can be detected in the developing mouse brain. 
Mouse brains of different ages were homogenized in lysis buffer, 
and equal amounts of protein were analyzed by SDS-PAGE and 
Western blotting using pcytL1 followed by peroxidase-conjugated 
secondary antibodies and ECL detection. 
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Inhibition of L1 ectodomain shedding blocks enhanced 
cell migration
 
We investigated the possibility that L1 shedding was crucial
for the enhanced migration of L1-CHO cells. Cells were
pretreated with BB-3103 and the haptotactic migration on
FN was analyzed. As shown in Fig. 6 C, the metalloprotein-
ase inhibitor reduced the migration of mL1-CHO cells back
to the level of CHO cells in a dose-dependent manner. The
inhibitor did not effect the migration of CHO cells, al-
though a slight reduction might have been undetected due
to the low level of migration of these cells. Similar results
were obtained with the Ro 31-9790 inhibitor (unpublished
data). We concluded that for L1-CHO cells, the metallopro-
teinase inhibitors exerted a similar effect on the haptotactic
migration as the mAb to the 
 
 
 
v
 
 
 
5 integrin. Both com-
pounds did not block the migration of the cells completely
Figure 5.  Expression of L1 enhances haptotactic migration of CHO cells. (A) FN at 10 mg/ml or BSA for control were coated on the 
backside of Transwell chambers. CHO, h/mL1-CHO or mL1-mutIII-CHO cells stably expressing L1 devoid of RGDs were seeded into the top 
chamber and allowed to transmigrate for 16 h at 37 C. Each determination was done in quadruplicate and transmigrated cells were stained 
from the back of the filter. The dye was eluted from the filter and measured at 595 nm. The amount of dye is proportional to the number of 
transmigrated cells. Values for the migration on BSA were below 0.25 OD units for each cell type. (B) Staining of CHO-transfected cells used 
in (A) with mAbs to human or mouse L1, respectively. (C) Analysis of CHO and mL1-CHO cell migration on vitronectin or laminin (each 
coated at 10 mg/ml). Analysis of migrated cells was done as described in A. (D) Dose–response curve for the migration of CHO and 
mL1-CHO cells. The assay was done as described in A. (E) FN or BSA for control were coated on LABTEK chamber slides, and the adhesion 
of CHO cells and transfectants was determined in the presence of 2 mM Ca 21 and 2 mM Mg21. Binding to BSA was below 50 cells/area. 
(F) Cells were grown on coverslips, stained with mAb 324 to mouse L1, and analyzed by fluorescence microscopy. (G) Cells were cultivated 
for 24 h and TCA-precipitated supernatants and cell lysates were analyzed. After SDS-PAGE, L1 was detected by Western blotting and ECL 
detection using anti L1 antibodies. 
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but rather selectively effected the enhanced cell migration
caused by the presence of L1.
 
Soluble L1 can stimulate migration of CHO cells
 
We hypothesized that cleaved L1 might deliver an autocrine
signal to the cells and thereby promote enhanced migration.
According to this hypothesis, the addition of soluble L1
should enhance the migration of CHO cells. To test this as-
sumption, CHO cells were first exposed to conditioned me-
dium from L1-positive cells, and the effect on the haptotactic
migration was analyzed. As shown in Fig. 7 A, the medium
from L1-CHO but not CHO cells could stimulate cell mi-
gration that was of similar magnitude as L1-CHO cells. The
stimulatory activity was also present in the conditioned me-
dium of AR tumor cells but was absent when AR cells or L1-
CHO cells were cultivated in the presence of BB-3103 in or-
der to block shedding. To further prove that the activity was
mediated by soluble L1, we used a recombinant L1-Fc pro-
tein (Fig. 7 B). As shown in Fig. 7 C, the L1-Fc protein but
not a control protein (SART-1-Fc) could stimulate CHO mi-
gration like conditioned medium containing native L1. We
concluded that soluble L1 can stimulate cell migration.
 
The effect of soluble L1 is blocked by a mAb to 
 
 
 
v
 
 
 
5 
and requires RGDs in L1
 
To determine whether the migration promoting effect of
soluble L1 required a direct binding to 
 
 
 
v
 
 
 
5 integrin, anti-
body blocking experiments were performed. Indeed, as
shown in Fig. 7 C, the migration-promoting effect of solu-
ble L1 was efficiently blocked in the presence of the anti-
body to 
 
 
 
v
 
 
 
5.
Previously, it has been shown that conserved RGD sites in
Ig domain 6 of L1 can support binding to integrins (Ruppert
et al., 1995; Ebeling et al., 1996; Montgomery et al., 1996;
Felding-Habermann et al., 1997; Oleszewski et al., 1999).
To analyze whether the RGD sites were necessary for the mi-
gration-promoting effect of soluble L1, we used an L1-Fc
protein in which the RGDs were mutated to RGE (L1-
Fc mut III). We have reported before that L1-Fc mut III
does not support integrin-mediated cell binding of mouse
Figure 6.  Inhibition of cell migration by antibodies and metalloproteinase inhibitor. (A) ML1-CHO cells or CHO cells were preincubated 
with the indicated mAbs at 10 mg/ml and added to the upper compartment of the Transwell chamber coated with FN from the backside. Note 
that antibody was present during the assay time. (B) Staining of CHO and mL1-CHO cells with a mAb to  v 5 integrin. (C) ML1-CHO cells or 
CHO cells were preincubated with the indicated amount of BB-3103 inhibitor for 2 h and then transferred to the upper compartment of the 
Transwell chamber. Each determination was done in quadruplicate and transmigrated cells were stained from the backside of the filter as 
described in Fig. 5 A. (D) Inhibition of cell migration by a mAb to the  5 integrin. ML1-CHO or CHO cells were preincubated with the mAbs 
at 10 mg/ml and added to the upper compartment of the Transwell chamber coated with FN. 
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B16F10 or IH3 cells (Oleszewski et al., 1999). As shown in
Fig. 7 C, the L1-Fc mut III proteins were unable to stimulate
CHO migration. Additional controls revealed that similar
amounts of L1-Fc and L1-Fc mut III fusion proteins were
present in the assay and that both Fc proteins could effi-
ciently bind to immobilized neurocan (unpublished data).
Like CHO cells, ML1–mutIII CHO cells were able to mi-
grate in response to soluble L1-Fc (unpublished data).
We next investigated whether the metalloproteinase-inhib-
iting effect on L1-CHO migration could be overcome by the
addition of exogenous L1. Indeed, as shown in Fig. 7 D, BB-
3103 pretreated L1-CHO cells migrated well on fibronectin
in response to L1-Fc protein. Collectively, these results sug-
gested that one effect of the metalloproteinase inhibitor was
to prevent the shedding of L1 and the subsequent autocrine/
paracrine signaling via 
 
 
 
v
 
 
 
5 integrins. This inhibition was
overcome by exogenous addition of soluble L1.
 
L1 cell surface expression levels affect cell migration
 
We examined whether the expression level of L1 could influ-
ence the rate of cell migration. SKOV3 cells were subjected
to several rounds of cell sorting and stable cell populations
with elevated or reduced expression of L1 were established.
As shown in Fig. 8 A, SKOV3hi expressed approximately
threefold higher levels of L1 as compared with SKOV3lo
cells (mean fluorescence 24–58). As established by ELISA,
SKOV3hi, and SKOV3lo cells also released different
amounts of soluble L1 into the medium (unpublished data).
Neither type of cell differed in their adhesion to fibronec-
tin (Fig. 8 B). However, the haptotaptic migration on fi-
Figure 7.  Exogenous addition of soluble L1 enhances migration of CHO cells. (A) 
CHO cells in the presence of the indicated conditioned media (1:10 final dilution) 
were seeded into the upper compartment of the Transwell chamber coated with FN 
from the backside and allowed to transmigrate for 16 h at 37 C. (B) Schematic 
representation of the L1-Fc and L1-Fc mut III fusion proteins. (C) CHO cells in the 
presence of the indicated Fc fusion protein (final concentration 0.67 mg/ml) were 
seeded into the upper compartment of the Transwell chamber. (D) ML1-CHO cells 
were pretreated with BB-3103 to prevent L1 shedding and haptotactic migration. 
Cells were then seeded together with the indicated Fc fusion proteins into the upper compartment of the Transwell chamber. Each 
determination was done in quadruplicates and transmigrated cells were stained from the backside of the filter as described in Fig. 5 A.
Figure 8.  The level of L1 expression affects cell mi-
gration. SKOV3 cell variants differing in the expression 
levels of L1 (SKOV3hi or SKOV3lo) were established by 
repeated FACS sorting. (A) Cytofluorographic staining 
of SKOV3hi or SKOV3lo cells with mAb UJ 127.11. (B) 
Analysis of cell adhesion and haptotactic cell migration 
of SKOV3hi or SKOV3lo cells. The assays were done as 
described in Figs. 5 E and 7 C, respectively. (C) Cells 
were preincubated with the indicated mAbs at 10 mg/
ml and transmigration on FN was tested as described in 
Fig. 6 A. (D) Cells were preincubated with the indicated 
mAbs at 10 mg/ml and transmigration on laminin was 
tested as described in Fig. 6 A. 
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bronectin was different. Fig. 8 B shows that SKOV3hi cells
migrated much better compared with SKOV3lo cells, but
this difference was no longer detectable when L1–Fc fusion
protein was added to the cells before the assay. The migration
was blocked in the presence of metalloproteinase inhibitors
(unpublished data). Additional mAb inhibition experiments
revealed that on fibronectin the migration of SKOV3hi and
SKOV3lo cells was inhibited mAb SAM-1 to the 
 
 
 
5 integrin
and on laminin by mAb GoH3 to the 
 
 
 
6 integrin, respec-
tively (Fig. 8, C and D). Most importantly, and in agreement
with the results obtained with CHO cells, a partial inhibition
by mAb P1F6 to the 
 
 
 
v 5 integrin was seen on both sub-
strates (Fig.8, C and D). Results similar to those presented
here for SKOV3 cells were obtained with high and low L1-
expressing variants of the ovarian tumor line OAW 42 (un-
published data). Thus, the level of cell surface expression of
L1 and hence the amount of L1 released by the cells affected
the haptotactic migration on two different substrates.
L1 shedding in AR cells involves ADAM10
ADAM10 has been identified as the principal  -secretase for
APP, and ADAM10 activity can be upregulated by treat-
ment of cells with MCD or the hydroxymethyl glutaryl-CoA
reductase inhibitor lovastatin (Lammich et al., 1999; Kojiro
et al., 2001). Given the observation that MCD treatment of
AR cells also drastically enhanced L1 shedding, we investi-
gated whether ADAM10 was a candidate sheddase for L1 re-
lease. Fig. 9 A shows that transient expression of a domi-
nant-negative form of ADAM10 (ADAM10 DN) could
nearly completely abolish the pervanadate or PMA-induced
release of L1 from AR cells. Overexpression of ADAM10
only marginally enhanced L1 release, suggesting that the
shedding of L1 was controlled by additional factors beyond
the expression level of shedding enzyme. Additional experi-
ments using antibodies to hemagglutinin and Flag epitopes
confirmed that ADAM10 and ADAM10 DN were ex-
pressed by the transfected cells (Fig. 9 B). Further studies us-
ing mL1-CHO cells showed a similar downregulation of L1
release by the ADAM10 DN construct (unpublished data).
Collectively, these results strongly imply that in both AR
and CHO cells the L1 release involved ADAM10.
The L1–150 plasmin fragment augments migration of 
CHO cells
It has been shown recently that the addition of plasmin to
L1-positive cells results in a dose-dependent loss of surface
L1 expression with the concomitant appearance of a 140–
150-kD soluble L1 species (L1–150) into the supernatant
(Nayeem et al., 1999). Cleavage occurs at a dibasic site in
the middle of the third FNIII repeat, thus, the released frag-
ment contains the RGD site(s) in the 6.Ig-domain. We
asked whether the plasmin fragment could substitute for the
metalloproteinase-released ectodomain of L1. AR cells in se-
rum-free medium were treated with a predetermined con-
centration of plasmin or plasmin plus the specific inhibitor
 2-antiplasmin, and supernatants and cell pellets were taken
for biochemical and functional analysis. To suppress the
metalloproteinase-mediated L1 release, all supernatants were
generated in the presence of Ro 31-9790 inhibitor. Fig. 10 A
shows that in the presence of Ro1plasmin, a substantial loss
of L1 from the cell pellet was observed which could be de-
tected with both L1 mAbs 5G3 and UJ 127.11. The latter
mAb also detected the L1-85 fragment remaining associated
with the cell pellet after plasmin cleavage. This is in agree-
ment with the notion that mAb UJ 127.11 recognizes an
epitope between the dibasic cleavage site and the plasma
membrane (Fig. 1 B), whereas mAb 5G3 reportedly binds to
the NH2 terminus of L1 (Silletti et al., 2000). Analysis of the
Figure 9. ADAM10 is involved in L1 shedding. (A) AR cells were 
transiently transfected with 10 mg plasmid DNA encoding HA-
tagged ADAM10 or Flag-tagged dominant-negative ADAM10 
(ADAM10 DN). 48 h after transfection, cells were stimulated with 
PMA or pervanadate to induce shedding. After 2 h, the supernatants 
were harvested and the cells lysed in lysis buffer. Cell lysates and 
conditioned media were analysed by ELISA for soluble L1. 
(B) Detection of HA-tagged ADAM10 or FLAG-tagged ADAM10 
DN in the lysate of transfected cells.
Figure 10.  The L1–150-kD plasmin 
fragment can also stimulate cell 
migration. AR cell were treated with Ro 
31-9790 inhibitor (Ro) in combination 
with plasmin and  2-antiplasmin for 6 h 
at 37 C. (A) Cells and supernatants were 
collected and analyzed by Western 
blotting using the indicated antibodies. 
(B) Supernatants of treated cultures 
were investigated for the ability to 
induce haptotactic migration of CHO 
cells as described in Fig. 7 A.Shedding of L1 adhesion molecule | Mechtersheimer et al.  669
supernatant from treated cultures indicated that in the pres-
ence of the metalloproteinase inhibitor, the formation of sol-
uble L1-200 was drastically reduced, and that plasmin addi-
tion resulted in the appearance of an expected 150-kD L1
fragment (Fig. 10 A). The formation of the 150-kD plasmin
fragment was blocked in the presence of  2-antiplasmin.
To analyze whether the plasmin fragment also could trig-
ger cell migration, the supernatants of treated cultures were
tested for the ability to induce haptotactic migration of
CHO cells. As shown in Fig. 10 B, supernatants containing
L1-200 or the plasmin fragment L1-150 could indeed in-
duce migration whereas control supernatants containing no
cleaved L1 could not. It should be noted that the L1-150
fragment was derived directly from the cell surface, and that
there was apparently more L1 protein present than in the
L1-200–containing supernatant. Therefore, it is possible
that on a molar basis, the L1-200 fragment is more potent in
the induction of migration than the L1-150 fragment.
Discussion
This report presents the first evidence that ectodomain
cleavage of L1 has a biological role by providing soluble L1,
which in turn can trigger cell migration. We find that L1-
32, a fragment comprising the transmembrane and cytoplas-
mic region of L1, remains associated with the membrane.
Not only is the fragment detected in varying amounts in hu-
man L1-positive carcinoma cell lines, but it is also in mouse
brain of stage P1. The presence of L1-32 declines with ad-
vancing age of the mice. Therefore, ectodomain cleavage of
L1 is not only a property of tumor cells, but it occurs in vivo
during brain development. In cultured cells, the cleavage
could be augmented by treatment with PMA and pervana-
date and was blocked by hydroxamate based metalloprotein-
ase inhibitors, suggesting that a metalloproteinase was in-
volved. Transfection studies indicated that in established cell
lines the shedding of L1 required ADAM10.
The starting point of our study was the observation that
L1-transfected CHO cells showed a three- to fivefold better
migration on fibronectin than CHO cells, and that this en-
hanced migration was blocked by the BB-3103 metallopro-
teinase inhibitor, suggesting a role of L1 shedding in the
migration process. It was possible that metalloproteinase in-
hibitors of the hydroxamate family might cause effects be-
yond the inhibition of ectodomain shedding. A recent study
has shown that batimastat (BB-94) can alter gene expression
levels in vivo (Krüger et al., 2001). Additional data revealed
that mAbs to  v 5 and L1 also inhibited migration of L1-
CHO cells to control levels. CHO cells are low in  v 5, but
express high levels of  5 1 which are used for migration on
fibronectin. Indeed, the migration and adhesion of both
types of cells on fibronectin were efficiently blocked by a
mAb to the  5 integrin. Thus, membrane-released L1 ex-
erted an enhancing effect on the basal migration of CHO
cells which involved the  v 5 integrin. We reasoned that
 v 5 could become directly engaged in migration or indi-
rectly by transmitting signals which accelerated the existing
migration machinery. The first option appeared less likely,
as several studies have shown that  v 5 only participates in
migration when cells receive additional signals like PMA or
growth factors (Klemke et al., 1994; Filardo et al., 1996). A
direct role of  v 5 in migration was also not consistent with
the complete blocking of the  5-specific mAb. In addition,
the mAb to  v 5 blocked partially the  6 integrin–medi-
ated migration on laminin, which is RGD independent. We
observed that soluble L1, either in a native form or as an
ectodomain Fc protein, could stimulate migration of CHO
cells, and that this could also be blocked by the mAb to
 v 5. The stimulation of migration required the presence of
RGDs in L1, consistent with the involvement of an integrin
in the signaling pathway. Moreover, the inhibition of CHO-
L1 migration by BB-3103 was fully restored by the addition
of soluble L1. Collectively, these data supported the notion
that soluble L1 was driving cell migration by binding to
 v 5, and that inhibition of L1 cleavage interrupted this au-
tocrine/paracrine loop. The results in the CHO system were
further corroborated by the analysis of SKOV3 cells differ-
ing in expression levels of L1. Cell variants with a higher
level of L1 migrated better than cells with lower level on
both fibronectin and laminin as substrate. As shown for fi-
bronectin, the addition of soluble L1 could restore the defect
of SKOV3lo cells. Thus, the amounts of L1 at the cell sur-
face and released by the cells appeared to be an important
factor in determining the rate of cell migration.
The results obtained with L1/L-selectin mutants deserve
a further notion. Whereas it is conceivable that CHO-5
(L-selectin/L1) cells did not migrate because the L-selectin
ectodomain could not stimulate, the situation with CHO-
62 cells (L1/L-selectin) is less clear. We observed that these
cells released significantly more L1 into the medium than
CHO-L1 cells, yet did not show haptotactic migration. Ad-
ditional experiments showed that the conditioned medium
of CHO-62 cells was able to stimulate vigorous migration of
CHO cells, suggesting that the ectodomain was functionally
active (unpublished data). However, in CHO-62, the L1
distribution was different compared with CHO-L1 cells. In
addition to surface expression, L1 was localized in a region
close to the nucleus. Moreover, the cells were altered in mor-
phology. It is quite possible that secondary effects like
changes in cytoskeletal organization are responsible for the
reduced haptotactic migration of CHO-62 cells compared
with L1-CHO wildtype cells. Another possibility could be
that the L-selectin cyttail actively inhibited cell migration.
Further analysis is needed to solve this issue.
Several previous studies have shown that soluble L1 can
influence axon growth and cell migration. It is well estab-
lished that immobilized, purified L1 or L1 presented on a
cell monolayer can serve as substrate for neurite outgrowth.
Several studies have provided evidence that soluble L1 can
stimulate neurite outgrowth of cerebellar neurons (Doherty
et al., 1995) or explants from embryonic chick brain (Su-
gawa et al., 1997). Indeed, soluble L1 has been suggested as
a potential pharmaceutical for the promotion of nerve re-
generation (Sugawa et al., 1997). In most cases, the growth-
and migration-promoting effects of L1 have been attributed
to L1 homophilic binding. However, Yip et al. (1998) have
demonstrated that the RGD motif in L1 also contributes to
neurite outgrowth by interacting with the  v 3 integrin
(Yip et al., 1998). Interestingly, in this study both ho-
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sal root ganglion cells, whereas neural retinal cells responded
only via homophilic binding (Yip et al., 1998). Soluble L1 is
also involved in the invasion and migration of malignant
gliomas (Izumoto et al., 1996). It was shown that C6 glioma
cells are stimulated to migrate by soluble L1 or L1 released
from transfected fibroblasts (Izumoto et al., 1996). Another
study from this group indicated that soluble L1, but not fi-
bronectin or tenascin, stimulated the invasion and migration
of C6 cells into cultured brain slices (Ohnishi et al., 1998).
Antibody inhibition experiments suggested that homophilic
binding of L1 was involved in stimulating glioma migration,
but a contribution of RGD motifs and integrin binding was
not tested (Izumoto et al., 1996). In our experiments, the
enhanced migration of L1-CHO was blocked by  v 5-spe-
cific mAbs and by mAb 324 to mouse L1. The latter anti-
body was previously found to block  5 1-mediated binding
of murine cells suggesting that the epitope recognized by this
mAb partially overlaps with the Ig domain 6 (Ruppert et al.,
1995). Also, the migration of CHO cell stimulated by solu-
ble L1 was inhibited by the  v 5-specific mAbs, and was
not observed with soluble L1 devoid of RGDs. This sug-
gested that the triggering signal involved binding to inte-
grins. We concluded that soluble L1 can stimulate cellular
responses like cell migration by binding and signaling through
integrins like  v 5.
Recent work has provided evidence that protein ec-
todomain cleavage regulates the function of membrane-
anchored growth factors and cytokines and is involved in
signal transduction processes (Blobel, 2000). The EGF re-
ceptor–mediated cell proliferation and migration of human
mammary epithelial cells can be blocked with metallopro-
teinase inhibitors, demonstrating that relevant EGF receptor
ligands need to be cleaved from the membrane to become
activated (Dong et al., 1999). Also, the EGF receptor trans-
activation caused by G protein–coupled receptors requires
metalloproteinase cleavage of the EGF-ligand heparin-bind-
ing EGF-like growth factor (Prenzel et al., 1999). Earlier
work has implicated ectodomain shedding as an important
element for EGF receptor signaling in development (Pe-
schon et al., 1998). Mice lacking TACE/ADAM17 have
phenotypes that resemble those seen in TGF-  and EGF re-
ceptor deficient animals (Peschon et al., 1998). Thus, the
membrane-anchored form of TGF-  has to be released by
proteolysis before it can fulfill its function as EGF receptor
ligand. ADAM mediated cleavage is also involved in Notch
signaling, which is important in regulating cell fate during
development (Artavanis-Tsakonas et al., 1999). The extra-
cellular domain of Notch can be cleaved by ADAM10 or
ADAM17 (Brou et al., 2000; Mumm et al., 2000). The cy-
toplasmic domain then enters the nucleus and, in coopera-
tion with a transcription factor, activates the Notch-depen-
dent genetic program (Artavanis-Tsakonas et al., 1999).
These examples support the notion that regulated proteoly-
sis is an important element in cell signaling and in the cross-
communication between different signaling systems (Prenzel
et al., 1999; Blobel, 2000). Our results show that cleavage of
a membrane-bound adhesion molecule can initiate integrin
signaling via its RGD-containing ectodomain. Many of the
intracellular signaling cascades influenced by soluble growth
factors and their receptors are also regulated by integrins
(Giancotti and Ruoslahti, 1999). In fact, growth factors and
integrin-mediated signals often act synergistically on cell
functions (Sieg et al., 2000).
Ectodomain cleavage of membrane molecules is acceler-
ated under pathological conditions such as inflammation
and apoptosis and by diverse stimuli (Hooper et al., 1997;
Subramanian et al., 1997). In addition to PMA and pervan-
adate, other agents that also induce shedding include cal-
cium ionophores, chemotactic peptides, cytokines, and
growth factors. Recently, it was shown that in A549 cells in-
tegrin ligation could augment the shedding of the hepato-
cyte growth factor receptor Met (Nath et al., 2001). Cells
grown on collagen released significantly more Met than
when cultivated on uncoated plastic and this induction in-
volved activation of the erk signaling pathway (Nath et al.,
2001). Although we have not yet tested any influence of in-
tegrin engagement in our system, it seems reasonable to as-
sume that shedding of L1 has to be maintained during cell
migration. Extracellular matrix components serving as sub-
strate for cell migration might induce signals that lead to
sustained cleavage. If indeed this is the case, it could explain
our observation that the enhanced migration of L1-CHO
cells was observed on diverse substrates like fibronectin,
laminin, and vitronectin. Indeed, in previous work we have
observed a link between the rate of L1 shedding and cyto-
skeletal changes (Gutwein et al., 2000). The cytoplasmic do-
main of L1 can associate with several kinases as well as with
the membrane skeletal protein ankyrin (Kamiguchi and
Lemmon, 1997). It is possible that for the regulated cleavage
these interactions are indispensable.
How then can the cleavage of L1 be enhanced in MCD
treated cells? A recent study has shown that the cleavage of
APP by the  -secretase ADAM10 was augmented in MCD
treated cells. The increase in enzymatic activity of ADAM10
was correlated with enhanced membrane fluidity (Kojiro et
al., 2001). The results presented in this study provide first
evidence that at least in cultured cell lines ADAM10 was in-
volved in the cleavage of L1, as a dominant-negative form of
ADAM10, that was shown before to suppress cleavage of
APP (Lammich et al., 1999), also affected the release of L1.
These data confirm and extend previous data showing that
ADAM10 activity can be augmented by cholesterol efflux of
the membrane. The exact molecular mechanism of this en-
hanced cleavage remains to be investigated. The similarity
with the APP system supports the notion that ADAM10 is
involved in L1 cleavage, very likely as the executing enzyme.
Direct biochemical evidence for the cleavage of L1 by
ADAM10 is presently not available. It is possible that
ADAM10 is inhibited by cholesterol itself or by a choles-
terol-dependent associated protein not yet identified. Per-
haps depletion of cholesterol increases encounter rates be-
tween L1 and the metalloproteinase. It remains to be seen
whether other ectodomain cleavage processes are also sensi-
tive to MCD treatment, or whether this is a particular fea-
ture of ADAM10. A further important question is whether
ADAM10 mediates L1 cleavage also during brain develop-
ment. We observed that cleavage of L1 in mouse brain was
highest around birth. Indeed, a coordinated expression of
APP and the  -secretase ADAM10 was reported in mouse
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The study of Nayeem et al. has provided the first evidence
that in addition to metalloproteinase(s) the release of a large
portion of the L1 ectodomain can be mediated by the plas-
min/plasminogen proteolytic system (Nayeem et al., 1999).
The activation of plasminogen to plasmin involves a cascade
of inhibitors and activators and requires binding to the cell
surface (Plow et al., 1995). In the brain, plasminogen and its
proteolytic fragment are abundant in the hippocampus
(Chen and Strickland, 1997). It has been known for a long
time that growth cones and migrating neurons release plas-
min-like proteases (Krystosek and Seeds, 1981). Proteolysis is
required during neurite outgrowth and neuronal migration is
retarded in mice lacking the tissue-type plasminogen activa-
tor (tPA) gene (Seeds et al., 1999). The proteolytic activation
of plasminogen by the urokinase-type plasminogen activator,
which is synthesized and secreted by many tumor cells, plays
an important role in tumor cell migration and invasion into
the surrounding tissue (Reuning et al., 1998). We demon-
strate here that the 150-kD fragment of L1 generated and re-
leased following plasmin cleavage can also promote cell mi-
gration as it contains the RGDs in the 6.Ig domain. This
raises the possibility that L1-150 can substitute for the com-
plete ectodomain of L1. The generation of L1-150 is evi-
dently dependent on the availability of plasminogen and a
cellular source of plasminogen activators and may therefore
be restricted. In contrast, as shown in this study the release of
L1 via metalloproteinase-mediated cleavage appears to be
more abundant, at least in cultured human tumor cells.
In summary, membrane-released L1 can promote cell mi-
gration in two ways. First, soluble L1 can be immobilized
into the surrounding matrix by the specific binding to lami-
nin (Montgomery et al., 1996) or the proteoglycan neuro-
can (Oleszewski et al., 2000). As shown before, immobilized
L1 can serve as a potent substrate for cell migration. Second,
as presented in this publication, soluble L1 fragments can di-
rectly interact with cells and stimulate cell migration. The
metalloproteinase-released ectodomain was able to stimulate
migration through autocrine/paracrine binding to integrins.
This is reminiscent of recent studies on ephrins and deleted
in colorectal cancer (DCC) showing that proteolytic cleav-
age plays a critical role in regulating cell movements. The
ability of soluble L1 to stimulate cell migration could be rel-
evant for migratory processes under many physiological and
pathophysiological conditions.
Materials and methods
Cells
Human breast tumor cell lines AR, MDA-231, MDA-435, SKBr3, and the
ovarian tumor cell lines SKOV3 and OAW42 were cultivated in DME sup-
plemented with 10% FBS at 37°C, 5% CO2, and 100% humidity. All cell
lines were obtained from the tumor bank of the German Cancer Research
Center (Heidelberg, Germany). CHO cells stably transfected with human
(hL1-CHO) or mouse L1 (mL1-CHO) were described before (Gutwein et al.,
2000). Ectodomain swapped fusion proteins between human L-selectin
(CD69L) and mouse L1 were constructed using PCR. In brief, the L1
ectodomain (amino acids M1 to E1123) were amplified and fused to the
transmembrane and cytoplasmic part of CD69L (amino acids P346 to
Y385). The ectodomain of CD69L (amino acids M1 to L319) was amplified
and fused to the COOH-terminal L1 fragment (amino acids I1090 to
E1260). The latter fragment comprises the 34 membrane-proximal amino
acids, the transmembrane and the cytoplasmic part of mouse L1. Mouse L1
devoid of RGDs (D555E and D564E) was constructed by site-directed mu-
tagenesis as described previously (Oleszewski et al., 1999). All cDNA con-
structs were cloned into pCDNA3 and confirmed by DNA sequencing.
Plasmid DNAs were transfected into CHO cells. G418 resistant colonies
were stained for L1 or CD69L followed by the respective secondary anti-
bodies, and positive cells were selected by several rounds of FACS sorting
(Beer et al., 1999). SKOV3 cells with high or low expression of L1
(SKOV3hi or SKOV3lo) were established by three rounds of FACS sorting
using an antibody to L1 and regrowth of sorted cells. A similar protocol was
applied to OAW42 cells. Cells were kept in DME and cultivated at 37 C,
5% CO2, and at 100% humidity. Plasmids encoding bovine HA-tagged
ADAM10 and a dominant-negative form of ADAM10 carrying a E384A sub-
stitution (Flag-tagged ADAM10 DN) were described previously (Lammich et
al., 1999). Transient expression was achieved by transfection of AR cells
with superfect (Stratagene). Analysis of shed L1 in the culture supernatants
by ELISA was done 48 h later (see below).
Chemicals and antibodies
mAb 324 against the mouse L1 adhesion molecule, mAb UJ 127.11
against human L1, and mAb 79 against mouse CD24 were described be-
fore (Ebeling et al., 1996; Beer et al., 1999).
mAb DREG56 against human CD69L was obtained from E.C. Butcher
(Stanford University, Stanford, CA). The mAb to  v 5 (P1F6) was obtained
from Chemicon, the mAb to human CD49e (SAM-1) was from Dianova,
the human L1 mAb 5G3 was obtained from Becton Dickinson, and the
mAb to CD49f (GoH3) was obtained from Beckman Coulter. Polyclonal
antibodies to the human L1 cytoplasmic domain (pcytL1) were produced
by immunizing a rabbit with a recombinant L1 cytoplasmic fragment ex-
pressed in bacteria. PMA, sodium vanadate, MCD, and laminin from pep-
sinized human placenta (laminin-10/11) were obtained from Sigma-
Aldrich. Vitronectin and bovine serum fibronectin were purchased from
Life Technologies, and human plasmin and  2-antiplasmin were obtained
from Calbiochem. BB-3103 was a gift of British Biotech, and Ro 31-9790
was obtained from Roche.
Immunfluorescence
The surface staining of cells with saturating amounts of mAbs, either hy-
bridoma supernatants or purified antibodies, and phenylephrine-conju-
gated goat antibodies to mouse Ig (Dianova) has been described elsewhere
(Ebeling et al., 1996). Stained cells were analyzed with a FACScan (Becton
Dickinson) or sorted using a FACS Vantage. Where indicated, cells were
grown on coverslips and fixed with 2% paraformaldehyde/PBS before fluo-
rescent staining and confocal microscopy analysis as previously described
(Krauss and Altevogt, 1999).
Analysis of L1 shedding
These assays were described previously (Gutwein et al., 2000). In brief,
2   106 cells were plated in 6-cm tissue culture plates in 5 ml of complete
medium. After 24 h at 37 C, the complete medium was replaced by 1.7 ml
serum-free culture medium for the indicated length of time. Cells remained
firmly attached to the plastic surface. Where indicated, PMA (50 ng/ml) or
pervanadate (200 mmolar) were included in the medium. A stock solution
of pervanadate was freshly prepared by mixing a solution of H2O2 and so-
dium vanadate (Gutwein et al., 2000). MCD treatment (10 mM final con-
centration) for 30 min at 37 C was done as described before (Krauss and
Altevogt, 1999). BB-3103 inhibitor was added 30 min before the addition
of PMA or pervanadate or before MCD treatment. Aliquots of the medium
were TCA precipitated or immunoprecipitated with mAb to L1 and ana-
lyzed for the presence of L1 by Western blotting. Alternatively, cells were
removed from the tissue culture plastic surface by PBS/5 mM EDTA treat-
ment for 5 min. Shedding was analyzed by resuspending the cells in se-
rum-free medium in 1.5 ml microfuge tubes at 37°C for 1 h in the presence
or absence of inducers and inhibitors. BB-3103 was used at 7 mM final
concentration. In some experiments Ro 31-9790 at a final concentration of
30 mM was used with essentially similar results. Cell pellets and culture
medium were separated by 10 min centrifugation in an Eppendorf centri-
fuge at 13,000   g. Culture supernatants from analyzed cells were TCA
precipitated and redissolved in twofold-concentrated, nonreducing SDS-
sample buffer. Cell pellets were lysed in lysis buffer (20 mM Tris/HCl, pH
8.0, containing 1% Triton X-100, 150 mM NaCl, 1 mM PMSF), cleared by
centrifugation, and mixed with twofold-concentrated reducing SDS sample
buffer. Mouse brains of different developmental stages were homogenized
in 1% Triton X-100/TBS/1mM orthovanadate, 1mM NaF/protease inhibi-
tors (leupeptin, pepstatin, aprotinin 10 mg/ml each, 10 mM EDTA, 2 mM
1,10 phenanthroline) at 4 C. The protein content of cell lysates was deter-
mined using the Biorad protein assay kit, and 20 mg protein was analyzed
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Plasmin treatment of cell cultures
2   106 adherent AR cells in serum-free medium were treated with plas-
min (0.6 U/ml) or plasmin plus  2-antiplasmin (1.2 U/ml) to neutralize
plasmin activity. Where indicated, Ro 31-9790 was included. Cells were
incubated for 6 h and supernatants were collected and protease inhibitors
(Roche completeZ mini) were added to prevent further cleavage. Aliquots
of each supernatant were TCA precipitated and analyzed for the presence
of L1 by Western blotting. For mAb 5G3 blots, samples were prepared by
heating at 80 C in nonreducing sample buffer as described (Nayeem et al.,
1999). Supernatants were also tested for the stimulation of CHO haptotac-
tic migration (see below).
Recombinant proteins
Fusion proteins containing the Fc portion of human IgG1 and the
ectodomain of mouse L1 or human L1 have been described in previous
publications (Oleszewski et al., 1999). The mouse L1–Fc mut III protein in
which both RGDs in the 6.Ig-like domain are mutated to RGE has also
been described (Oleszewski et al., 1999). The production and character-
ization of SART-1-Fc will be reported in a separate publication (unpub-
lished data). Plasmid-DNA was transfected into COS-7 cells and superna-
tants containing the Fc fusion protein were collected. Fc-fusion proteins
were purified by protein A Sepharose chromatography and analyzed and
quantified using a human Fc-specific capture ELISA with purified human
IgG as standard (Oleszewski et al., 1999).
ELISA for the detection of soluble human L1
For the detection of soluble L1, 96-well flexible microtiter plates (Falcon
3912; Becton Dickinson) were coated with 1 mg/ml of capturing antibody
(anti-L1 mAb 5G3) overnight. Wells were blocked with 3% BSA/PBS for 45
min and then incubated for 1 h with tissue culture supernatants containing
soluble L1. After five washes with BSA/PBS, the wells were incubated for 1 h
with biotin-conjugated mAb UJ127.11 followed by streptavidin-conju-
gated peroxidase (Dianova) using BMP as substrate. The color reaction
was stopped by the addition of 10 mM H2SO4 and analyzed at 450 nm
using an ELISA reader. Human L1–Fc protein served as an internal stan-
dard for the assay.
Biochemical analysis
Samples were separated by SDS-PAGE under nonreducing conditions and
transferred to an Immobilon membrane using semi-dry blotting. After
blocking with 5% skim milk in TBS, the blots were developed with the re-
spective primary antibody (mAbs UJ127.11, 5G3 or pcytL1) followed by
peroxidase conjugated secondary antibody and ECL detection.
Transmigration assays
For the haptotactic cell migration assay, fibronectin, vitronectin, laminin, or
BSA (each at 10 mg/ml) were coated for 90 min on the backside of Transwell
chambers (Costar, 6.5 mm diam, 5-mm pore size). Cells (105 or as otherwise
indicated) in RPMI 1640 medium containing 0.5% BSA were seeded into
the upper chamber and allowed to transmigrate to the lower compartment
for 16 h at 37 C. For mAb blocking the cells were preincubated at 10 mg/ml
with the respective mAb for 30 min at 37 C before onset of the assay. To
quantify transmigrated cells, the inner chamber was removed and cleaned
carefully with a cotton swab to remove the non-migrated cells. Migrated
cells adherent to the bottom of the membrane were stained with crystal vio-
let solution. The membranes were extensively washed in water and the re-
maining stain was eluted with 10% acidic acid. The eluted dye was mea-
sured at 595 nm in an ELISA reader. Each determination was done in
quadruplicate and the data are given as mean values   SEM.
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